ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO Press release LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. October 07, 2019
ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. January 02, 2019
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 17, 2021
ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU Press release Key Updates April 03, 2017
ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients Press release LEIDEN, the Netherlands, June 26, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 26, 2015
ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC Press release LEIDEN, the Netherlands, Sept. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 27, 2016
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 16, 2021
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa Press release Key Updates November 29, 2017
ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board Press release Key Updates November 09, 2017
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. September 09, 2019